Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, Chang SC, Grunkemeier G, Leidner R, Bell RB, Weinberg AD. · 2018
Read Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. by Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, Chang SC, Grunkemeier G, Leidner R, Bell RB, Weinberg AD. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6045647.txt.
Description
Duhen and co-authors find a marker pair for tumor-reactive T cells. Their research article appeared in Nature Communications. Finding T cells that truly attack a tumor matters. Such cells could guide diagnosis and new therapies. Most T cells inside tumors are mere bystanders.
Cells carrying both CD39 and CD103 stood out. They were enriched for tumor-reactive cells. The pattern held across six cancer types. These cells killed the patient's own tumor cells in tests. Their receptor mix differed from other T cells. Clones were expanded inside tumors but rare in blood. In head and neck cancer, more such cells meant better survival. Readers get a practical way to spot useful T cells.
Catalog record
| CREATOR | Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, Chang SC, Grunkemeier G, Leidner R, Bell RB, Weinberg AD. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |